achieving mfs and improved quality of life in nmcrpc with darolutamide
Published 5 years ago • 76 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
8:22
ep. 9: neurological aes and quality of life in treating nmcrpc
-
1:52
prostate cancer: quality of life maintained with darolutamide
-
5:36
anti-psma antibody radiolabeled with 177lu improves mfs in high-risk nmcrpc
-
1:46
examining the impact of darolutamide on pain and qol in patients with nonmetastatic crpc
-
34:34
active surveillance of prostate cancer with yushen qian, md
-
40:03
psma & lutetium-177 in 2022 | eugene kwon, md | diy combat manual for beating prostate cancer part 4
-
1:32:31
unlocking the power of modern therapeutic regimens for prostate cancer
-
3:06
how ar therapy has changed the nmcrpc treatment landscape
-
3:03
nonmetastatic crpc: mfs and ar-targeted agents
-
0:54
the addition of darolutamide to adt reduces risk of metastases in crpc
-
2:46
aramis: darolutamide in patients with nmcrpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:57
aramis: efficacy and safety of darolutamide in nmcrpc
-
15:06
comparing real world evidence to phase iii data on apalutamide for nmcrpc
-
1:18:00
urowebinar: identification and management of patients with nmcrpc
-
20:33
dr aseem samar | role of darolutamide in nmcrpc
-
2:50
the differences between mcrpc and nmcrpc
-
3:38
the nccn and aua guidelines for treating nmcrpc
-
1:08
aramis: efficacy and safety of darolutamide in nmcrpc
-
12:03
mri-guided focal therapy: initial quality-of-life and oncologic outcomes
-
2:17
advanced prostate cancer and patient-centric treatment
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc